Description of the 474 patients with PsA participating in the weighting and validation study
| Characteristic | Mean (SD) (range) or N (%)* | Range across countries of mean values or proportions† |
|---|---|---|
| Female sex | 235 (50.2%) | 32.5–81.8% |
| Age, years | 50.4 (12.6) (20.8–80.1) | 42.6–55.1 |
| Disease duration, years | 9.6 (9.4) (0.0–41.9) | 5.4–16.2 |
| Formal education, years | 12.5 (3.8) (0–20) | 9.9–14.9 |
| Proportion of patients fulfilling CASPAR criteria | 351 (75.5%) | 23.8–94.6% |
| Current disease-modifying drug | 306 (66.8%) | 36.5–85.0% |
| Current biological treatment | 202 (46.8%) | 23.5–79.1% |
| Swollen joint count (0–66) | 2.4 (4.1) (0–36) | 0.6–5.1 |
| Tender joint count (0–68) | 5.4 (8.0) (0–52) | 1.8–14.0 |
| Current skin psoriasis | 286 (65.2%) | 10.5–97.3% |
| DAS28-ESR | 2.8 (1.4) (0.0–7.1) | 2.2–4.1 |
| HAQ (0–3) | 0.81 (0.70) (0–2.75) | 0.63–1.01 |
| Patient global assessment (0–10) | 4.1 (2.8) (0–10) | 2.9–5.1 |
| Pain (0–10) | 4.7 (2.9) (0–10) | 3.6–6.2 |
| DLQI (0–30) | 4.3 (5.7) (0–30) | 1.7–8.8 |
| EQ-5D | 0.60 (0.30) (−0.59 to 1) | 0.47–0.72 |
| SF-36 physical component | 37.7 (10.5) (13.5–58.3) | 32.1–40.3 |
| SF-36 mental component | 47.0 (11.5) (15.1–68.9) | 42.9–54.8 |
Fewer than 10% of the data were missing for all elements except swollen joint count (10.2% missing data), DAS28 (27.0%) and SF-36 (21.9%).
*Percentages are % of available data.
†Range of means or percentages: minimum and maximum values for means or percentages observed in participating countries.
DAS28, Disease Activity Score (28 joints); DLQI, Dermatology Life Quality Index; EQ-5D, EuroQol-5D; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; SF-36, short form (36) generic quality of life scale.